JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Начало・Списък с акции・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

37.97 1.55

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

37.54

Максимум

38.05

Ключови измерители
By Trading Economics
Приходи	-547M -179M
Продажби	-515M 28M
Марж на печалбата	-643.397
Служители	609
EBITDA	-546M -148M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+11.66% upside

Дивиденти
By Dow Jones
Следващи печалби	25.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	3B 5.3B
Предишно отваряне	36.42
Предишно затваряне	37.97

Настроения в новините

By Acuity

22%

78%

42 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

11.5 / 12.23 Подкрепа & съпротива

Arrowhead Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.10.2025 г., 18:41 ч. UTC

Печалби

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24.10.2025 г., 18:31 ч. UTC

Печалби

Correction to Procter & Gamble to Focus on Innovation

24.10.2025 г., 16:25 ч. UTC

Значими двигатели на пазара

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24.10.2025 г., 21:24 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

24.10.2025 г., 21:24 ч. UTC

Пазарно говорене

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24.10.2025 г., 21:07 ч. UTC

Печалби

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24.10.2025 г., 20:58 ч. UTC

Печалби

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

24.10.2025 г., 20:40 ч. UTC

Печалби

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24.10.2025 г., 20:24 ч. UTC

Печалби

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24.10.2025 г., 20:23 ч. UTC

Печалби

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24.10.2025 г., 20:13 ч. UTC

Печалби

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 20:07 ч. UTC

Пазарно говорене

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24.10.2025 г., 19:40 ч. UTC

Пазарно говорене

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24.10.2025 г., 19:35 ч. UTC

Пазарно говорене

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24.10.2025 г., 19:33 ч. UTC

Печалби

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24.10.2025 г., 19:29 ч. UTC

Пазарно говорене

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24.10.2025 г., 18:52 ч. UTC

Печалби

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24.10.2025 г., 18:41 ч. UTC

Печалби

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24.10.2025 г., 18:03 ч. UTC

Печалби

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24.10.2025 г., 18:02 ч. UTC

Печалби

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24.10.2025 г., 18:00 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24.10.2025 г., 16:57 ч. UTC

Печалби

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24.10.2025 г., 16:54 ч. UTC

Пазарно говорене

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24.10.2025 г., 16:44 ч. UTC

Пазарно говорене

Печалби

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24.10.2025 г., 16:39 ч. UTC

Пазарно говорене

Печалби

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24.10.2025 г., 16:33 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 16:23 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

24.10.2025 г., 16:07 ч. UTC

Печалби

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Arrowhead Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

11.66% нагоре

12-месечна прогноза

Среден 42.43 USD 11.66%

Висок 80 USD

Нисък 17 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Arrowhead Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Arrowhead Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

11.5 / 12.23Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Настроение

By Acuity

42 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.